US Patent Issued to Bristol-Myers Squibb on Feb. 10 for "Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d 3 ) pyridazine-3-carboxamide" (New Jersey Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,665, issued on Feb. 10, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d 3 ) pyridazine-3-carboxamide" was invented by Yanlei Zhang (Princeton, N.J.) and Michael A. Galella (Kendall Park, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form A is a neat crystalline form. Characterization data for Form A are disclosed."

The patent was filed on Aug. 11, 2021...